Autoimmune Disease Diagnostics Market - Global Forecast 2026-2032

The Autoimmune Disease Diagnostics Market is projected to reach USD 3.16 Billion in 2026. It is expected to continue growing at a CAGR of 6.51%, reaching USD 4.64 Billion by 2032.

Autoimmune disease diagnostics are moving from episodic, symptom-led testing to earlier, multi-marker, and longitudinal assessment across rheumatology, gastroenterology, endocrinology, neurology, nephrology, and dermatology. Demand is supported by the high clinical burden of autoimmune disorders, delayed diagnosis in conditions such as systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroid disease, type 1 diabetes, inflammatory bowel disease, and celiac disease, and the need to distinguish inflammatory, infectious, malignant, and genetic mimics.

The market is anchored by established technologies such as indirect immunofluorescence assays, ELISA, chemiluminescent immunoassays, complement testing, HLA typing, tissue transglutaminase testing, anti-cyclic citrullinated peptide testing, antinuclear antibody testing, extractable nuclear antigen panels, and disease-specific autoantibody panels. Adoption is increasingly shaped by multiplex immunoassays, laboratory automation, digital pathology, companion-style biomarker strategies, and data integration with electronic health records to improve diagnostic confidence and patient monitoring.

Transformative Shifts in the Diagnostic Landscape

The autoimmune disease diagnostics landscape is being reshaped by three structural shifts: earlier risk detection, higher-throughput laboratory platforms, and more specialized clinical decision support. Clinicians increasingly require tests that support differential diagnosis, disease activity monitoring, flare prediction, organ involvement assessment, and treatment stratification rather than single-point confirmation. This is especially relevant because many autoimmune diseases have overlapping symptoms and may require combined interpretation of serology, inflammatory markers, imaging, biopsy findings, and clinical history.

Regulatory and quality expectations are also changing. The European Union In Vitro Diagnostic Regulation has raised requirements for clinical evidence, post-market surveillance, performance documentation, and notified body review, while U.S. laboratories continue to navigate evolving oversight of laboratory-developed tests. These shifts favor manufacturers and laboratories with validated assays, traceable controls, harmonized reporting, scalable automation, and strong medical education programs that help reduce false positives, false negatives, and unnecessary downstream testing.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the value of autoimmune diagnostics by improving pattern recognition, workflow triage, and interpretation across complex datasets. AI-enabled image analysis can support antinuclear antibody immunofluorescence pattern classification, while machine learning models can integrate serology, inflammatory markers, genomics, medications, symptoms, imaging, pathology, and longitudinal clinical data to identify patients needing specialist referral or closer monitoring.

The cumulative impact is operational as well as clinical. AI can help laboratories reduce manual review burden, flag inconsistent results, prioritize high-risk samples, support reflex testing pathways, and strengthen quality management. Its strongest near-term value is expected in decision support and laboratory efficiency, provided models are clinically validated, bias-tested, explainable, cybersecurity-protected, and integrated into regulated diagnostic workflows with clinician oversight.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

In Asia-Pacific, autoimmune disease diagnostics benefit from expanding hospital networks, rising private diagnostics investment, and broad adoption of automated immunoassay platforms in China, India, Japan, South Korea, and Australia. Population scale, growing chronic disease awareness, medical tourism, and increasing specialist access support test utilization, although reimbursement variability, urban-rural access gaps, and uneven availability of subspecialty immunology services remain important constraints.

North America remains a high-value region because of advanced clinical laboratories, strong rheumatology and gastroenterology networks, broad use of molecular and multiplex testing, and active adoption of digital health and electronic health record integration. Europe is shaped by strong public health systems, CE-IVD requirements, clinical guideline adherence, and high standards for assay validation under the In Vitro Diagnostic Regulation. Latin America shows rising demand in Brazil and Mexico, supported by private laboratory chains, urban specialty care expansion, and growing awareness of autoimmune thyroid disease, rheumatoid arthritis, and celiac disease. The Middle East, particularly Gulf health systems, is investing in advanced hospital diagnostics, reference laboratories, and tertiary care infrastructure, while Africa’s development is tied to reference laboratory capacity, infectious disease differential diagnosis, workforce training, and improved access to specialist testing in major urban centers.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are characterized by growing private hospital groups, expanding medical tourism, and increasing use of centralized reference laboratories, especially in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. This creates demand for scalable autoimmune serology, celiac disease testing, thyroid autoantibody testing, and connective tissue disease panels. The GCC benefits from government-backed healthcare modernization, tertiary hospital investment, population screening initiatives, and demand for imported advanced diagnostic platforms that support specialist care pathways.

The European Union is a critical regulatory and commercialization benchmark because IVDR compliance affects assay classification, clinical evidence, post-market surveillance, and market access timelines. BRICS countries create large-volume opportunities, led by China, India, and Brazil, but require pricing discipline, localization, reimbursement awareness, and strong distributor or laboratory partnerships. G7 markets lead in specialty diagnostics adoption, reimbursement sophistication, digital laboratory infrastructure, and clinical research, while NATO countries collectively support resilient supply chains, laboratory interoperability, cybersecurity readiness, and healthcare security priorities relevant to uninterrupted essential diagnostic testing.

Key Country Insights Across Major Autoimmune Diagnostics Markets

The United States leads in autoimmune disease diagnostics through high test utilization, advanced reference laboratories, FDA-cleared platforms, broad insurance-linked clinical pathways, and strong adoption of multiplex panels. Canada benefits from publicly funded care, centralized provincial laboratory models, and evidence-based utilization management, while Mexico’s demand is supported by urban private diagnostics, expanding specialty clinics, and cross-border healthcare activity. Brazil is the leading Latin American opportunity due to its large population, specialty care presence, public-private laboratory networks, and rising demand for rheumatology, thyroid, and gastrointestinal autoimmune testing.

In Europe, the United Kingdom emphasizes National Health Service pathways, clinical governance, and evidence-based testing; Germany combines advanced laboratory infrastructure with strong reimbursement discipline and high automation; France, Italy, and Spain show steady demand for rheumatoid arthritis, celiac disease, autoimmune thyroid disease, systemic autoimmune rheumatic disease, and inflammatory bowel disease diagnostics; and Russia relies on major urban centers for advanced immunology testing and specialist referral. In Asia-Pacific, China and India offer scale and fast laboratory modernization supported by hospital expansion and private diagnostics growth, Japan and South Korea emphasize quality, automation, precision medicine, and standardized workflows, and Australia benefits from guideline-driven testing, robust specialist referral systems, and strong laboratory accreditation practices.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated assay portfolios that address high-burden conditions such as rheumatoid arthritis, lupus, celiac disease, autoimmune thyroid disease, inflammatory bowel disease, type 1 diabetes, antiphospholipid syndrome, and autoimmune liver disease. Portfolio strategy should combine established serology with multiplex, molecular, and digital interpretation capabilities that improve diagnostic specificity, support reflex testing, and reduce unnecessary repeat testing.

Companies should invest in evidence generation, health economics, laboratory workflow automation, payer-facing clinical utility data, and education for clinicians and laboratory professionals. Regional success will depend on IVDR readiness, U.S. regulatory preparedness, local reference ranges, quality-controlled distribution, reagent supply resilience, interoperability with laboratory information systems, and partnerships with hospitals, reference laboratories, academic centers, and digital health platforms.

Research Methodology

This executive summary applies a secondary research methodology using publicly available, verifiable sources, including regulatory guidance, peer-reviewed clinical literature, professional society recommendations, government health data, disease burden studies, reimbursement frameworks, laboratory accreditation standards, and public health reports. Insights are triangulated across clinical adoption, laboratory infrastructure, regulatory requirements, technology maturity, guideline relevance, and regional access patterns.

Market interpretation is based on evidence-linked indicators rather than unverified assumptions. Key inputs include diagnostic guideline relevance, assay validation requirements, automation adoption, patient access dynamics, specialist density, reimbursement environment, laboratory quality systems, and the role of reference laboratories in scaling autoimmune disease testing. No market sizing, market share, or forecasting assumptions are used in this analysis.

Conclusion

Autoimmune disease diagnostics are becoming more precise, automated, and data-integrated as healthcare systems seek earlier detection, better differential diagnosis, and improved disease monitoring. Established serology remains essential, but differentiation is shifting toward validated multiplex panels, AI-enabled interpretation, robust quality systems, standardized reporting, and evidence-based clinical utility.

Organizations that align innovation with regulatory compliance, affordability, laboratory efficiency, supply reliability, and physician confidence will be best positioned to advance clinical adoption. The strongest opportunities lie in markets where specialist access, reimbursement support, laboratory accreditation, and diagnostic infrastructure converge to support timely autoimmune disease diagnosis and long-term patient management.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.1.1. Persistent Need for Earlier and More Accurate Diagnosis
4.3.1.2. Laboratory Automation and Standardization
4.3.1.3. Expansion of Clinically Governed Multiplex Testing
4.3.1.4. Biomarker and Longitudinal-Disease Research
4.3.1.5. Centralization of Specialty Laboratory Workflows
4.3.2. Key Restraints
4.3.2.1. Clinical Heterogeneity and Interpretive Complexity
4.3.2.2. Reimbursement and Procurement Pressure
4.3.2.3. Regulatory Evidence and Portfolio-Certification Burden
4.3.2.4. Installed-Base Switching Friction
4.3.2.5. Limited Cost Pass-Through
4.3.3. Key Opportunities
4.3.3.1. Disease-Specific Reflex and Multi-Analyte Pathways
4.3.3.2. Scalable Automation for Independent Laboratories
4.3.3.3. Risk, Monitoring, and Treatment-Response Applications
4.3.3.4. Asia-Pacific Localization and Access
4.3.3.5. Informatics and Lifecycle Services
4.3.4. Key Challenges
4.3.4.1. Regulatory Portfolio Prioritization
4.3.4.2. Cross-Method Comparability and Harmonization
4.3.4.3. Supply and Product-Lifecycle Continuity
4.3.4.4. Channel and Service Consistency
4.3.4.5. Translation of Biomarkers into Clinical Utility
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Autoimmune Disease Diagnostics Market, by Offering

7.1. Introduction
7.2. Assays, Reagents & Consumables
7.3. Instruments
7.3.1. Immunoassay Analyzers
7.3.2. IFA Systems
7.3.3. Microplate Readers
7.4. Services
7.4.1. Diagnostic Support
7.4.2. Calibration
7.5. Software & Informatics
7.5.1. Laboratory Automation
7.5.2. Laboratory Information/Analysis Software
7.5.3. Diagnostic Interpretation

8. Autoimmune Disease Diagnostics Market, by Detection Technology

8.1. Introduction
8.2. Chemiluminescence Immunoassay
8.3. Enzyme Immunoassay
8.3.1. ELISA
8.3.2. Fluorescence Enzyme Immunoassay
8.4. Indirect Immunofluorescence Assay
8.5. Array Immunoassay
8.5.1. Particle-Based Array
8.5.2. Planar Microarray
8.6. Immunoturbidimetry & Nephelometry
8.7. Immunoblot
8.8. Visual Agglutination Assay
8.9. Lateral Flow Immunoassay
8.10. Functional Cell-Based Bioassay

9. Autoimmune Disease Diagnostics Market, by Assay Multiplexing

9.1. Introduction
9.2. Single-Analyte Assays
9.3. Multi-Analyte Panels

10. Autoimmune Disease Diagnostics Market, by Test Type

10.1. Introduction
10.2. Autoantibodies & Immunologic Test
10.2.1. Antinuclear Antibodies
10.2.2. Cyclic Citrullinated Peptide Antibodies
10.3. Imaging Tests
10.3.1. Magnetic Resonance Imaging
10.3.2. Positron Emission Tomography
10.4. Genetic Tests
10.4.1. Molecular Tests
10.4.2. Chromosomal Tests

11. Autoimmune Disease Diagnostics Market, by Clinical Indication

11.1. Introduction
11.2. Connective Tissue Diseases
11.3. Endocrine Autoimmunity
11.4. Rheumatoid Arthritis
11.5. Gastrointestinal Autoimmunity
11.6. Neurologic & Neuromuscular Autoimmunity
11.7. Autoimmune Vasculitis
11.8. Autoimmune Liver Diseases
11.9. Antiphospholipid Syndrome

12. Autoimmune Disease Diagnostics Market, by Clinical Function

12.1. Introduction
12.2. Diagnosis & Differential Diagnosis
12.3. Clinically Indicated Screening & Triage
12.4. Disease Course & Relapse Monitoring
12.5. Prognosis & Risk Assessment
12.6. Treatment Response Monitoring

13. Autoimmune Disease Diagnostics Market, by End User

13.1. Introduction
13.2. Hospital
13.3. Independent Clinical Laboratories
13.4. Physician Office & Clinic Laboratories

14. Autoimmune Disease Diagnostics Market, by Workflow Automation

14.1. Introduction
14.2. Fully Automated Processing
14.3. Semi-Automated Processing
14.4. Manual Processing

15. Autoimmune Disease Diagnostics Market, by Distribution Channel

15.1. Introduction
15.2. Direct Sales
15.3. Distributor & Reseller Sales
15.4. Online Sales

16. Autoimmune Disease Diagnostics Market, by Region

16.1. Introduction
16.2. North America
16.3. Europe
16.4. Asia-Pacific
16.5. Latin America
16.6. Middle East
16.7. Africa

17. Autoimmune Disease Diagnostics Market, by Group

17.1. Introduction
17.2. NATO
17.3. G7
17.4. European Union
17.5. BRICS
17.6. ASEAN
17.7. GCC

18. Autoimmune Disease Diagnostics Market, by Country

18.1. Introduction
18.2. United States
18.3. China
18.4. Japan
18.5. Germany
18.6. France
18.7. United Kingdom
18.8. Canada
18.9. Italy
18.10. Australia
18.11. India
18.12. South Korea
18.13. Brazil
18.14. Spain
18.15. Mexico
18.16. Russia

19. Competitive Landscape

19.1. Market Share Analysis, 2025
19.2. Market Concentration Analysis, 2025
19.2.1. Concentration Ratio (CR)
19.2.2. Herfindahl Hirschman Index (HHI)
19.3. Recent Developments & Impact Analysis, 2025
19.4. Product Portfolio Analysis, 2025
19.5. Benchmarking Analysis, 2025

20. Company Profiles

20.1. Thermo Fisher Scientific Inc.
20.2. Werfen, S.A.
20.3. Revvity, Inc.
20.4. Bio-Rad Laboratories, Inc.
20.5. F. Hoffmann-La Roche Ltd.
20.6. Siemens Healthineers AG
20.7. Abbott Laboratories
20.8. DiaSorin S.p.A.
20.9. Sebia S.A.
20.10. Grifols, S.A.
20.11. Trinity Biotech plc
20.12. HUMAN Gesellschaft für Biochemica und Diagnostica mbH
20.13. Aesku.Group GmbH
20.14. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
20.15. Shenzhen YHLO Biotech Co., Ltd.
20.16. Shenzhen New Industries Biomedical Engineering Co., Ltd.
20.17. HOB Biotech Group Corp., Ltd.
20.18. Medical & Biological Laboratories Co., Ltd.
20.19. J. Mitra & Co. Pvt. Ltd.
20.20. BIOSYSTEMS S.A.
20.21. Svar Life Science AB
20.22. A. Menarini Diagnostics S.r.l.
20.23. DIESSE Diagnostica Senese S.p.A.
20.24. ZEUS Scientific, Inc.
20.25. Immuno Concepts, N.A. Ltd.
20.26. Wama Produtos para Laboratório Ltda
20.27. Erba Lachema s.r.o.
20.28. Autobio Diagnostics Co., Ltd.
20.29. R-Biopharm AG
20.30. Medipan GmbH
20.31. GA Generic Assays GmbH
20.32. D-tek s.a.
20.33. VIRAMED BIOTECH AG
20.34. Demeditec Diagnostics GmbH
20.35. BIOSYNEX SA
20.36. Gold Standard Diagnostics Frankfurt GmbH
20.37. MIKROGEN GmbH
20.38. Eurobio Scientific
20.39. Progentec Diagnostics, Inc.
20.40. PROTIA. iNC.
20.41. Quest Diagnostics, Inc.
20.42. RSR Limited
20.43. SD Biosensor, INC.
20.44. Shanghai Kehua Bio-Engineering Co., Ltd.

21. Key Experts

List of Figures

FIGURE 1. Global Autoimmune Disease Diagnostics Market, Years Considered for the Study
FIGURE 2. Global Autoimmune Disease Diagnostics Market, Research Design
FIGURE 3. Global Autoimmune Disease Diagnostics Market, Research Framework
FIGURE 4. Global Autoimmune Disease Diagnostics Market, Data Triangulation
FIGURE 5. Global Autoimmune Disease Diagnostics Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Autoimmune Disease Diagnostics Market Size, by Offering, 2025 vs 2032 (%)
FIGURE 7. Global Autoimmune Disease Diagnostics Market Size, by Offering, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Autoimmune Disease Diagnostics Market Size, by Detection Technology, 2025 vs 2032 (%)
FIGURE 9. Global Autoimmune Disease Diagnostics Market Size, by Detection Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Autoimmune Disease Diagnostics Market Size, by Assay Multiplexing, 2025 vs 2032 (%)
FIGURE 11. Global Autoimmune Disease Diagnostics Market Size, by Assay Multiplexing, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Autoimmune Disease Diagnostics Market Size, by Test Type, 2025 vs 2032 (%)
FIGURE 13. Global Autoimmune Disease Diagnostics Market Size, by Test Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Autoimmune Disease Diagnostics Market Size, by Clinical Indication, 2025 vs 2032 (%)
FIGURE 15. Global Autoimmune Disease Diagnostics Market Size, by Clinical Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Autoimmune Disease Diagnostics Market Size, by Clinical Function, 2025 vs 2032 (%)
FIGURE 17. Global Autoimmune Disease Diagnostics Market Size, by Clinical Function, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Autoimmune Disease Diagnostics Market Size, by End User, 2025 vs 2032 (%)
FIGURE 19. Global Autoimmune Disease Diagnostics Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Autoimmune Disease Diagnostics Market Size, by Workflow Automation, 2025 vs 2032 (%)
FIGURE 21. Global Autoimmune Disease Diagnostics Market Size, by Workflow Automation, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global Autoimmune Disease Diagnostics Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 23. Global Autoimmune Disease Diagnostics Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 24. Global Autoimmune Disease Diagnostics Market Size, by Region, 2025 vs 2032 (%)
FIGURE 25. Global Autoimmune Disease Diagnostics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 26. Global Autoimmune Disease Diagnostics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 27. Global Autoimmune Disease Diagnostics Market Size, by Country, 2025 vs 2032 (%)
FIGURE 28. Global Autoimmune Disease Diagnostics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 29. Global Autoimmune Disease Diagnostics Market Share, by Key Player, 2025

List of Tables

TABLE 1. Global Autoimmune Disease Diagnostics Market Segmentation & Coverage
TABLE 2. Global Autoimmune Disease Diagnostics Market Size, 2017-2032 (USD Million)
TABLE 3. Global Autoimmune Disease Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 4. Global Assays, Reagents & Consumables Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Assays, Reagents & Consumables Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Assays, Reagents & Consumables Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Instruments Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Instruments Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Instruments Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Immunoassay Analyzers Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Immunoassay Analyzers Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Immunoassay Analyzers Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global IFA Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global IFA Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global IFA Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Microplate Readers Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Microplate Readers Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Microplate Readers Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Diagnostic Support Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Diagnostic Support Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Diagnostic Support Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Calibration Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Calibration Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Calibration Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Software & Informatics Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Software & Informatics Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Software & Informatics Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Laboratory Automation Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Laboratory Automation Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Laboratory Automation Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Laboratory Information/Analysis Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Laboratory Information/Analysis Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Laboratory Information/Analysis Software Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Diagnostic Interpretation Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Diagnostic Interpretation Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Diagnostic Interpretation Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Autoimmune Disease Diagnostics Market Size, by Detection Technology, 2017-2032 (USD Million)
TABLE 41. Global Chemiluminescence Immunoassay Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Chemiluminescence Immunoassay Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Chemiluminescence Immunoassay Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Enzyme Immunoassay Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Enzyme Immunoassay Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Enzyme Immunoassay Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global ELISA Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global ELISA Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global ELISA Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Fluorescence Enzyme Immunoassay Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Fluorescence Enzyme Immunoassay Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Fluorescence Enzyme Immunoassay Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Indirect Immunofluorescence Assay Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Indirect Immunofluorescence Assay Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Indirect Immunofluorescence Assay Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Array Immunoassay Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Array Immunoassay Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Array Immunoassay Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Particle-Based Array Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Particle-Based Array Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Particle-Based Array Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Planar Microarray Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Planar Microarray Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Planar Microarray Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Immunoturbidimetry & Nephelometry Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Immunoturbidimetry & Nephelometry Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Immunoturbidimetry & Nephelometry Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Immunoblot Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Immunoblot Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Immunoblot Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Visual Agglutination Assay Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Visual Agglutination Assay Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Visual Agglutination Assay Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Lateral Flow Immunoassay Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Lateral Flow Immunoassay Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Lateral Flow Immunoassay Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Functional Cell-Based Bioassay Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Functional Cell-Based Bioassay Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Functional Cell-Based Bioassay Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Autoimmune Disease Diagnostics Market Size, by Assay Multiplexing, 2017-2032 (USD Million)
TABLE 81. Global Single-Analyte Assays Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Single-Analyte Assays Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Single-Analyte Assays Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Multi-Analyte Panels Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Multi-Analyte Panels Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Multi-Analyte Panels Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Autoimmune Disease Diagnostics Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 88. Global Autoantibodies & Immunologic Test Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Autoantibodies & Immunologic Test Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Autoantibodies & Immunologic Test Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Antinuclear Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Antinuclear Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Antinuclear Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Cyclic Citrullinated Peptide Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Cyclic Citrullinated Peptide Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Cyclic Citrullinated Peptide Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Imaging Tests Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Imaging Tests Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Imaging Tests Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Magnetic Resonance Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Magnetic Resonance Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Magnetic Resonance Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Positron Emission Tomography Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Positron Emission Tomography Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Positron Emission Tomography Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Genetic Tests Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Genetic Tests Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Genetic Tests Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Molecular Tests Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Molecular Tests Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Molecular Tests Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Chromosomal Tests Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Global Chromosomal Tests Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. Global Chromosomal Tests Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. Global Autoimmune Disease Diagnostics Market Size, by Clinical Indication, 2017-2032 (USD Million)
TABLE 116. Global Connective Tissue Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Global Connective Tissue Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. Global Connective Tissue Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 119. Global Endocrine Autoimmunity Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Global Endocrine Autoimmunity Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. Global Endocrine Autoimmunity Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. Global Rheumatoid Arthritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Global Rheumatoid Arthritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. Global Rheumatoid Arthritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. Global Gastrointestinal Autoimmunity Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global Gastrointestinal Autoimmunity Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global Gastrointestinal Autoimmunity Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global Neurologic & Neuromuscular Autoimmunity Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Global Neurologic & Neuromuscular Autoimmunity Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. Global Neurologic & Neuromuscular Autoimmunity Market Size, by Country, 2017-2032 (USD Million)
TABLE 131. Global Autoimmune Vasculitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Global Autoimmune Vasculitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. Global Autoimmune Vasculitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 134. Global Autoimmune Liver Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 135. Global Autoimmune Liver Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. Global Autoimmune Liver Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 137. Global Antiphospholipid Syndrome Market Size, by Region, 2017-2032 (USD Million)
TABLE 138. Global Antiphospholipid Syndrome Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. Global Antiphospholipid Syndrome Market Size, by Country, 2017-2032 (USD Million)
TABLE 140. Global Autoimmune Disease Diagnostics Market Size, by Clinical Function, 2017-2032 (USD Million)
TABLE 141. Global Diagnosis & Differential Diagnosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 142. Global Diagnosis & Differential Diagnosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. Global Diagnosis & Differential Diagnosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 144. Global Clinically Indicated Screening & Triage Market Size, by Region, 2017-2032 (USD Million)
TABLE 145. Global Clinically Indicated Screening & Triage Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. Global Clinically Indicated Screening & Triage Market Size, by Country, 2017-2032 (USD Million)
TABLE 147. Global Disease Course & Relapse Monitoring Market Size, by Region, 2017-2032 (USD Million)
TABLE 148. Global Disease Course & Relapse Monitoring Market Size, by Group, 2017-2032 (USD Million)
TABLE 149. Global Disease Course & Relapse Monitoring Market Size, by Country, 2017-2032 (USD Million)
TABLE 150. Global Prognosis & Risk Assessment Market Size, by Region, 2017-2032 (USD Million)
TABLE 151. Global Prognosis & Risk Assessment Market Size, by Group, 2017-2032 (USD Million)
TABLE 152. Global Prognosis & Risk Assessment Market Size, by Country, 2017-2032 (USD Million)
TABLE 153. Global Treatment Response Monitoring Market Size, by Region, 2017-2032 (USD Million)
TABLE 154. Global Treatment Response Monitoring Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. Global Treatment Response Monitoring Market Size, by Country, 2017-2032 (USD Million)
TABLE 156. Global Autoimmune Disease Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 158. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 159. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 160. Global Independent Clinical Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 161. Global Independent Clinical Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 162. Global Independent Clinical Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 163. Global Physician Office & Clinic Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 164. Global Physician Office & Clinic Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 165. Global Physician Office & Clinic Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 166. Global Autoimmune Disease Diagnostics Market Size, by Workflow Automation, 2017-2032 (USD Million)
TABLE 167. Global Fully Automated Processing Market Size, by Region, 2017-2032 (USD Million)
TABLE 168. Global Fully Automated Processing Market Size, by Group, 2017-2032 (USD Million)
TABLE 169. Global Fully Automated Processing Market Size, by Country, 2017-2032 (USD Million)
TABLE 170. Global Semi-Automated Processing Market Size, by Region, 2017-2032 (USD Million)
TABLE 171. Global Semi-Automated Processing Market Size, by Group, 2017-2032 (USD Million)
TABLE 172. Global Semi-Automated Processing Market Size, by Country, 2017-2032 (USD Million)
TABLE 173. Global Manual Processing Market Size, by Region, 2017-2032 (USD Million)
TABLE 174. Global Manual Processing Market Size, by Group, 2017-2032 (USD Million)
TABLE 175. Global Manual Processing Market Size, by Country, 2017-2032 (USD Million)
TABLE 176. Global Autoimmune Disease Diagnostics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 177. Global Direct Sales Market Size, by Region, 2017-2032 (USD Million)
TABLE 178. Global Direct Sales Market Size, by Group, 2017-2032 (USD Million)
TABLE 179. Global Direct Sales Market Size, by Country, 2017-2032 (USD Million)
TABLE 180. Global Distributor & Reseller Sales Market Size, by Region, 2017-2032 (USD Million)
TABLE 181. Global Distributor & Reseller Sales Market Size, by Group, 2017-2032 (USD Million)
TABLE 182. Global Distributor & Reseller Sales Market Size, by Country, 2017-2032 (USD Million)
TABLE 183. Global Online Sales Market Size, by Region, 2017-2032 (USD Million)
TABLE 184. Global Online Sales Market Size, by Group, 2017-2032 (USD Million)
TABLE 185. Global Online Sales Market Size, by Country, 2017-2032 (USD Million)
TABLE 186. Global Autoimmune Disease Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 187. North America Autoimmune Disease Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 188. North America Autoimmune Disease Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 189. North America Autoimmune Disease Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 190. North America Autoimmune Disease Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 191. North America Autoimmune Disease Diagnostics Market Size, by Software & Informatics, 2017-2032 (USD Million)
TABLE 192. North America Autoimmune Disease Diagnostics Market Size, by Detection Technology, 2017-2032 (USD Million)
TABLE 193. North America Autoimmune Disease Diagnostics Market Size, by Enzyme Immunoassay, 2017-2032 (USD Million)
TABLE 194. North America Autoimmune Disease Diagnostics Market Size, by Array Immunoassay, 2017-2032 (USD Million)
TABLE 195. North America Autoimmune Disease Diagnostics Market Size, by Assay Multiplexing, 2017-2032 (USD Million)
TABLE 196. North America Autoimmune Disease Diagnostics Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 197. North America Autoimmune Disease Diagnostics Market Size, by Autoantibodies & Immunologic Test, 2017-2032 (USD Million)
TABLE 198. North America Autoimmune Disease Diagnostics Market Size, by Imaging Tests, 2017-2032 (USD Million)
TABLE 199. North America Autoimmune Disease Diagnostics Market Size, by Genetic Tests, 2017-2032 (USD Million)
TABLE 200. North America Autoimmune Disease Diagnostics Market Size, by Clinical Indication, 2017-2032 (USD Million)
TABLE 201. North America Autoimmune Disease Diagnostics Market Size, by Clinical Function, 2017-2032 (USD Million)
TABLE 202. North America Autoimmune Disease Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. North America Autoimmune Disease Diagnostics Market Size, by Workflow Automation, 2017-2032 (USD Million)
TABLE 204. North America Autoimmune Disease Diagnostics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 205. Europe Autoimmune Disease Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 206. Europe Autoimmune Disease Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 207. Europe Autoimmune Disease Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 208. Europe Autoimmune Disease Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 209. Europe Autoimmune Disease Diagnostics Market Size, by Software & Informatics, 2017-2032 (USD Million)
TABLE 210. Europe Autoimmune Disease Diagnostics Market Size, by Detection Technology, 2017-2032 (USD Million)
TABLE 211. Europe Autoimmune Disease Diagnostics Market Size, by Enzyme Immunoassay, 2017-2032 (USD Million)
TABLE 212. Europe Autoimmune Disease Diagnostics Market Size, by Array Immunoassay, 2017-2032 (USD Million)
TABLE 213. Europe Autoimmune Disease Diagnostics Market Size, by Assay Multiplexing, 2017-2032 (USD Million)
TABLE 214. Europe Autoimmune Disease Diagnostics Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 215. Europe Autoimmune Disease Diagnostics Market Size, by Autoantibodies & Immunologic Test, 2017-2032 (USD Million)
TABLE 216. Europe Autoimmune Disease Diagnostics Market Size, by Imaging Tests, 2017-2032 (USD Million)
TABLE 217. Europe Autoimmune Disease Diagnostics Market Size, by Genetic Tests, 2017-2032 (USD Million)
TABLE 218. Europe Autoimmune Disease Diagnostics Market Size, by Clinical Indication, 2017-2032 (USD Million)
TABLE 219. Europe Autoimmune Disease Diagnostics Market Size, by Clinical Function, 2017-2032 (USD Million)
TABLE 220. Europe Autoimmune Disease Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 221. Europe Autoimmune Disease Diagnostics Market Size, by Workflow Automation, 2017-2032 (USD Million)
TABLE 222. Europe Autoimmune Disease Diagnostics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 223. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 224. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 225. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 226. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 227. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by Software & Informatics, 2017-2032 (USD Million)
TABLE 228. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by Detection Technology, 2017-2032 (USD Million)
TABLE 229. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by Enzyme Immunoassay, 2017-2032 (USD Million)
TABLE 230. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by Array Immunoassay, 2017-2032 (USD Million)
TABLE 231. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by Assay Multiplexing, 2017-2032 (USD Million)
TABLE 232. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 233. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by Autoantibodies & Immunologic Test, 2017-2032 (USD Million)
TABLE 234. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by Imaging Tests, 2017-2032 (USD Million)
TABLE 235. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by Genetic Tests, 2017-2032 (USD Million)
TABLE 236. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by Clinical Indication, 2017-2032 (USD Million)
TABLE 237. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by Clinical Function, 2017-2032 (USD Million)
TABLE 238. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 239. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by Workflow Automation, 2017-2032 (USD Million)
TABLE 240. Asia-Pacific Autoimmune Disease Diagnostics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 241. Latin America Autoimmune Disease Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 242. Latin America Autoimmune Disease Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 243. Latin America Autoimmune Disease Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 244. Latin America Autoimmune Disease Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 245. Latin America Autoimmune Disease Diagnostics Market Size, by Software & Informatics, 2017-2032 (USD Million)
TABLE 246. Latin America Autoimmune Disease Diagnostics Market Size, by Detection Technology, 2017-2032 (USD Million)
TABLE 247. Latin America Autoimmune Disease Diagnostics Market Size, by Enzyme Immunoassay, 2017-2032 (USD Million)
TABLE 248. Latin America Autoimmune Disease Diagnostics Market Size, by Array Immunoassay, 2017-2032 (USD Million)
TABLE 249. Latin America Autoimmune Disease Diagnostics Market Size, by Assay Multiplexing, 2017-2032 (USD Million)
TABLE 250. Latin America Autoimmune Disease Diagnostics Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 251. Latin America Autoimmune Disease Diagnostics Market Size, by Autoantibodies & Immunologic Test, 2017-2032 (USD Million)
TABLE 252. Latin America Autoimmune Disease Diagnostics Market Size, by Imaging Tests, 2017-2032 (USD Million)
TABLE 253. Latin America Autoimmune Disease Diagnostics Market Size, by Genetic Tests, 2017-2032 (USD Million)
TABLE 254. Latin America Autoimmune Disease Diagnostics Market Size, by Clinical Indication, 2017-2032 (USD Million)
TABLE 255. Latin America Autoimmune Disease Diagnostics Market Size, by Clinical Function, 2017-2032 (USD Million)
TABLE 256. Latin America Autoimmune Disease Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 257. Latin America Autoimmune Disease Diagnostics Market Size, by Workflow Automation, 2017-2032 (USD Million)
TABLE 258. Latin America Autoimmune Disease Diagnostics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 259. Middle East Autoimmune Disease Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 260. Middle East Autoimmune Disease Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 261. Middle East Autoimmune Disease Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 262. Middle East Autoimmune Disease Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 263. Middle East Autoimmune Disease Diagnostics Market Size, by Software & Informatics, 2017-2032 (USD Million)
TABLE 264. Middle East Autoimmune Disease Diagnostics Market Size, by Detection Technology, 2017-2032 (USD Million)
TABLE 265. Middle East Autoimmune Disease Diagnostics Market Size, by Enzyme Immunoassay, 2017-2032 (USD Million)
TABLE 266. Middle East Autoimmune Disease Diagnostics Market Size, by Array Immunoassay, 2017-2032 (USD Million)
TABLE 267. Middle East Autoimmune Disease Diagnostics Market Size, by Assay Multiplexing, 2017-2032 (USD Million)
TABLE 268. Middle East Autoimmune Disease Diagnostics Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 269. Middle East Autoimmune Disease Diagnostics Market Size, by Autoantibodies & Immunologic Test, 2017-2032 (USD Million)
TABLE 270. Middle East Autoimmune Disease Diagnostics Market Size, by Imaging Tests, 2017-2032 (USD Million)
TABLE 271. Middle East Autoimmune Disease Diagnostics Market Size, by Genetic Tests, 2017-2032 (USD Million)
TABLE 272. Middle East Autoimmune Disease Diagnostics Market Size, by Clinical Indication, 2017-2032 (USD Million)
TABLE 273. Middle East Autoimmune Disease Diagnostics Market Size, by Clinical Function, 2017-2032 (USD Million)
TABLE 274. Middle East Autoimmune Disease Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 275. Middle East Autoimmune Disease Diagnostics Market Size, by Workflow Automation, 2017-2032 (USD Million)
TABLE 276. Middle East Autoimmune Disease Diagnostics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 277. Africa Autoimmune Disease Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 278. Africa Autoimmune Disease Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 279. Africa Autoimmune Disease Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 280. Africa Autoimmune Disease Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 281. Africa Autoimmune Disease Diagnostics Market Size, by Software & Informatics, 2017-2032 (USD Million)
TABLE 282. Africa Autoimmune Disease Diagnostics Market Size, by Detection Technology, 2017-2032 (USD Million)
TABLE 283. Africa Autoimmune Disease Diagnostics Market Size, by Enzyme Immunoassay, 2017-2032 (USD Million)
TABLE 284. Africa Autoimmune Disease Diagnostics Market Size, by Array Immunoassay, 2017-2032 (USD Million)
TABLE 285. Africa Autoimmune Disease Diagnostics Market Size, by Assay Multiplexing, 2017-2032 (USD Million)
TABLE 286. Africa Autoimmune Disease Diagnostics Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 287. Africa Autoimmune Disease Diagnostics Market Size, by Autoantibodies & Immunologic Test, 2017-2032 (USD Million)
TABLE 288. Africa Autoimmune Disease Diagnostics Market Size, by Imaging Tests, 2017-2032 (USD Million)
TABLE 289. Africa Autoimmune Disease Diagnostics Market Size, by Genetic Tests, 2017-2032 (USD Million)
TABLE 290. Africa Autoimmune Disease Diagnostics Market Size, by Clinical Indication, 2017-2032 (USD Million)
TABLE 291. Africa Autoimmune Disease Diagnostics Market Size, by Clinical Function, 2017-2032 (USD Million)
TABLE 292. Africa Autoimmune Disease Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 293. Africa Autoimmune Disease Diagnostics Market Size, by Workflow Automation, 2017-2032 (USD Million)
TABLE 294. Africa Autoimmune Disease Diagnostics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 295. Global Autoimmune Disease Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 296. NATO Autoimmune Disease Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 297. NATO Autoimmune Disease Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 298. NATO Autoimmune Disease Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 299. NATO Autoimmune Disease Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 300. NATO Autoimmune Disease Diagnostics Market Size, by Software & Informatics, 2017-2032 (USD Million)
TABLE 301. NATO Autoimmune Disease Diagnostics Market Size, by Detection Technology, 2017-2032 (USD Million)
TABLE 302. NATO Autoimmune Disease Diagnostics Market Size, by Enzyme Immunoassay, 2017-2032 (USD Million)
TABLE 303. NATO Autoimmune Disease Diagnostics Market Size, by Array Immunoassay, 2017-2032 (USD Million)
TABLE 304. NATO Autoimmune Disease Diagnostics Market Size, by Assay Multiplexing, 2017-2032 (USD Million)
TABLE 305. NATO Autoimmune Disease Diagnostics Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 306. NATO Autoimmune Disease Diagnostics Market Size, by Autoantibodies & Immunologic Test, 2017-2032 (USD Million)
TABLE 307. NATO Autoimmune Disease Diagnostics Market Size, by Imaging Tests, 2017-2032 (USD Million)
TABLE 308. NATO Autoimmune Disease Diagnostics Market Size, by Genetic Tests, 2017-2032 (USD Million)
TABLE 309. NATO Autoimmune Disease Diagnostics Market Size, by Clinical Indication, 2017-2032 (USD Million)
TABLE 310. NATO Autoimmune Disease Diagnostics Market Size, by Clinical Function, 2017-2032 (USD Million)
TABLE 311. NATO Autoimmune Disease Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 312. NATO Autoimmune Disease Diagnostics Market Size, by Workflow Automation, 2017-2032 (USD Million)
TABLE 313. NATO Autoimmune Disease Diagnostics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 314. G7 Autoimmune Disease Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 315. G7 Autoimmune Disease Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 316. G7 Autoimmune Disease Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 317. G7 Autoimmune Disease Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 318. G7 Autoimmune Disease Diagnostics Market Size, by Software & Informatics, 2017-2032 (USD Million)
TABLE 319. G7 Autoimmune Disease Diagnostics Market Size, by Detection Technology, 2017-2032 (USD Million)
TABLE 320. G7 Autoimmune Disease Diagnostics Market Size, by Enzyme Immunoassay, 2017-2032 (USD Million)
TABLE 321. G7 Autoimmune Disease Diagnostics Market Size, by Array Immunoassay, 2017-2032 (USD Million)
TABLE 322. G7 Autoimmune Disease Diagnostics Market Size, by Assay Multiplexing, 2017-2032 (USD Million)
TABLE 323. G7 Autoimmune Disease Diagnostics Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 324. G7 Autoimmune Disease Diagnostics Market Size, by Autoantibodies & Immunologic Test, 2017-2032 (USD Million)
TABLE 325. G7 Autoimmune Disease Diagnostics Market Size, by Imaging Tests, 2017-2032 (USD Million)
TABLE 326. G7 Autoimmune Disease Diagnostics Market Size, by Genetic Tests, 2017-2032 (USD Million)
TABLE 327. G7 Autoimmune Disease Diagnostics Market Size, by Clinical Indication, 2017-2032 (USD Million)
TABLE 328. G7 Autoimmune Disease Diagnostics Market Size, by Clinical Function, 2017-2032 (USD Million)
TABLE 329. G7 Autoimmune Disease Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 330. G7 Autoimmune Disease Diagnostics Market Size, by Workflow Automation, 2017-2032 (USD Million)
TABLE 331. G7 Autoimmune Disease Diagnostics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 332. European Union Autoimmune Disease Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 333. European Union Autoimmune Disease Diagnostics Market Size, by Offering

Companies Mentioned

Thermo Fisher Scientific Inc.
Werfen, S.A.
Revvity, Inc.
Bio-Rad Laboratories, Inc.
F. Hoffmann-La Roche Ltd.
Siemens Healthineers AG
Abbott Laboratories
DiaSorin S.p.A.
Sebia S.A.
Grifols, S.A.
Trinity Biotech plc
HUMAN Gesellschaft für Biochemica und Diagnostica mbH
Aesku.Group GmbH
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Shenzhen YHLO Biotech Co., Ltd.
Shenzhen New Industries Biomedical Engineering Co., Ltd.
HOB Biotech Group Corp., Ltd.
Medical & Biological Laboratories Co., Ltd.
J. Mitra & Co. Pvt. Ltd.
BIOSYSTEMS S.A.
Svar Life Science AB
A. Menarini Diagnostics S.r.l.
DIESSE Diagnostica Senese S.p.A.
ZEUS Scientific, Inc.
Immuno Concepts, N.A. Ltd.
Wama Produtos para Laboratório Ltda
Erba Lachema s.r.o.
Autobio Diagnostics Co., Ltd.
R-Biopharm AG
Medipan GmbH
GA Generic Assays GmbH
D-tek s.a.
VIRAMED BIOTECH AG
Demeditec Diagnostics GmbH
BIOSYNEX SA
Gold Standard Diagnostics Frankfurt GmbH
MIKROGEN GmbH
Eurobio Scientific
Progentec Diagnostics, Inc.
PROTIA. iNC.
Quest Diagnostics, Inc.
RSR Limited
SD Biosensor, INC.
Shanghai Kehua Bio-Engineering Co., Ltd.

Table Information

Report Attribute	Details
No. of Pages	192
Published	September 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 3.16 Billion
Forecasted Market Value ( USD ) by 2032	$ 4.64 Billion
Compound Annual Growth Rate	6.5%
Regions Covered	Global
No. of Companies Mentioned	44

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3162EUR$3,545USD£2,719GBP €3514EUR$3,939USD£3,021GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4784EUR$5,363USD£4,113GBP €5316EUR$5,959USD£4,570GBP

Transformative Shifts in the Diagnostic Landscape

Cumulative Impact of Artificial Intelligence

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

Key Country Insights Across Major Autoimmune Diagnostics Markets

Actionable Recommendations for Industry Leaders

Research Methodology

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Autoimmune Disease Diagnostics Market - Products, Disease Types and Test Types

Autoimmune Disease Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report by Type, Product, Test, End Use, Region, and Segment Forecasts, 2026-2033

Autoimmune Disease Diagnostics Market Report by Type, Indication, End-User, Countries and Company Analysis 2026-2034

Autoimmune Disease Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034